NIH Archives -

Patients/ Views & Analysis/ Views and analysis

Steps to building a more patient-centric industry

mike.hammerton@pharmaphorum.com CISCRIP, clinical trials, cloud platforms, data, demographics, diversity, equity, NIH, patient centricity, technology 0 Comment

Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in

Steps to building a more patient-centric industry

https://pharmaphorum.com/views-and-analysis/steps-to-building-a-more-patient-centric-industry/

Digital/ Views & Analysis/ Views and analysis

The NIH on accelerating research using diverse biomedical datasets

Jessica Hagen All of Us, biomedical research, biosamples, data, diversity, mobile engagement asset, NIH, personalised medicine 0 Comment

Martin Mendoza, PhD, director of health equity and health science policy for the All of Us Research Program

The NIH on accelerating research using diverse biomedical datasets

https://pharmaphorum.com/views-and-analysis/the-nih-on-accelerating-research-using-diverse-biomedical-datasets/

News/ News/ R&D

NIH starts trial of Moderna’s mRNA Nipah virus vaccine

Phil Taylor Moderna, mRNA, NIAID, NIH, Nipah virus, vaccine 0 Comment

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection

NIH starts trial of Moderna’s mRNA Nipah virus vaccine

https://pharmaphorum.com/news/nih-starts-trial-of-modernas-mrna-nipah-virus-vaccine/

News/ News/ Sales and Marketing

FDA clears Gilead’s Veklury for COVID outpatients

Phil Taylor antiviral, coronavirus, COVID-19, fda, Gilead Sciences, NIH, Veklury 0 Comment

The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with

FDA clears Gilead’s Veklury for COVID outpatients

https://pharmaphorum.com/news/fda-clears-gileads-veklury-for-covid-outpatients/

Market Access/ News/ News

Moderna squares off with US government over COVID jab patent

Phil Taylor access, coronavirus, COVID-19, COVID-19 vaccine, Intellectual property, Moderna, NIH 0 Comment

After being hailed as a triumph of public-private drug development, Moderna’s partnership with the US government on its

Moderna squares off with US government over COVID jab patent

https://pharmaphorum.com/news/moderna-squares-off-with-us-over-covid-shot-patents/

News/ News/ R&D

More malaria hope as NIH antibody protects against infection

Phil Taylor antibody, infectious disease, Malaria, NIAID, NIH, parasitology, R&D 0 Comment

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH)

More malaria hope as NIH antibody protects against infection

https://pharmaphorum.com/news/more-malaria-hope-as-antibody-protects-against-infection/

Digital/ News/ News

NIH digital tool aims to boost enrolment into Alzheimer’s studies

Phil Taylor Alzheimer's disease, clinical trials, digital, digital health, NIH, patient retention, recruitment 0 Comment

With a string of new drugs for Alzheimer’s disease making their way through late-stage clinical testing, the demand

NIH digital tool aims to boost enrolment into Alzheimer’s studies

https://pharmaphorum.com/news/nih-digital-tool-aims-to-boost-enrolment-into-alzheimers-studies/

News/ News/ Patients

NIH abandons convalescent plasma trial in mild COVID

Phil Taylor convalescent plasma, coronavirus, COVID-19, immunology, NIH 0 Comment

Another trial of convalescent plasma in people with COVID-19 has missed the mark, this time in mild to

NIH abandons convalescent plasma trial in mild COVID

https://pharmaphorum.com/news/nih-abandons-convalescent-plasma-trial-in-mild-covid/

News/ News/ R&D

US experts stress over safety of AZ’s COVID-19 vaccine

Richard Staines AstraZeneca, coroanvirus, COVID-19, NIH, vaccine 0 Comment

US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine

US experts stress over safety of AZ’s COVID-19 vaccine

https://pharmaphorum.com/news/us-experts-stress-over-safety-of-azs-covid-19-vaccine/

Trending

NIH

Login